Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Side effects, contraindications, and what to discuss with your provider before starting
Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects
The content below explains the scientific background, proposed research mechanisms, typical application areas, storage expectations, reconstitution considerations where applicable, and quality-control points that support careful experimental planning
Gramer G, Hoffmann GF (2020) Vitamin B12 deficiency in newborns and their mothersnovel approaches to early detection, treatment and prevention of a global health issue
US$ 26.25
US$ 27.00
US$ 21.98
US$ 21.23
US$ 27.04
US$ 22.38
US$ 20.18
US$ 20.76
US$ 26.98
US$ 24.59
US$ 29.55
